MP
PEAR

Mangrove Partners’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Mangrove Partners’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-299,693
Closed -$2.96M – 406
2021
Q2 		$2.96M Buy
+299,693
New +$2.94M 0.3% 71

Other funds holding PEAR

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $276M AUM 15.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Mangrove Partners's PEAR Position: Q3 2021 in Review

Mangrove Partners sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q3 2021, closing a stake of 299,693 shares — an estimated $2.96M sold.

Mangrove Partners first reported a position in PEAR in Q2 2021 and held it in 1 quarter. The position peaked at $2.96M in Q2 2021. 85 funds tracked by Wall St. Rank hold PEAR as of Q3 2021.

  • Mangrove Partners reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
  • Mangrove Partners sold 299,693 Pear Therapeutics, Inc. Class A Common Stock shares in Q3 2021, an estimated $2.96M.
  • Mangrove Partners first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 1 quarter.
  • Mangrove Partners's Pear Therapeutics, Inc. Class A Common Stock position peaked at $2.96M in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q3 2021.

Based on Mangrove Partners's 13F filing for Q3 2021, filed 15 Nov 2021.